Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.
The development of anti-factor VIII (FVIII) antibodies (Abs), also called inhibitors, is currently one of the most serious complications arising during the treatment of hemophilia A patients. Improved prevention and eradication of these Abs remain a challenge both for clinicians and scientists. Numerous studies in the literature have reported on their epitope specificity, on their mechanism of FVIII inactivation, as well as on the methods used for their detection. In this review, we summarize the current knowledge on the nature (isotypes, kinetic properties), epitope properties, and mechanisms of action of anti-FVIII Abs. Furthermore, we present methods for detection and epitope characterization of anti-FVIII Abs with emphasis on the Luminex technique susceptible to facilitate the monitoring of changes in the epitope specificity of these Abs.
Lavigne-Lissalde
Géraldine
G
CNRS FRE 3009, Cap Delta/Parc Euromédecine, Montpellier, France. geraldinelavigne@hotmail.com
Rothschild
Chantal
C
Pouplard
Claire
C
Lapalud
Priscilla
P
Gruel
Yves
Y
Schved
Jean-François
JF
Granier
Claude
C
D000818:Animals; D001323:Autoantibodies / Q000097:blood* / Q000276:immunology; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood* / Q000276:immunology; D018604:Epitope Mapping; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000737:chemistry / Q000276:immunology*; D006467:Hemophilia A / Q000276:immunology*; D006801:Humans; D051379:Mice
D001323:Autoantibodies; D019774:Blood Coagulation Factor Inhibitors; D005169:Factor VIII